Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gynecologic 1

Conditions

Multiple Myeloma 1Gynecologic Cancer 1

Interventions

pembrolizumab 222Carboplatin 215Cisplatin 203Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 114Cyclophosphamide 102Pemetrexed 100Dexamethasone 100Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 94Doxorubicin 91Fluorouracil 88Bevacizumab 84Leucovorin 73Nivolumab 72Rituximab 71Vincristine 68durvalumab 65Lenalidomide 64Radiation 62atezolizumab 61Irinotecan 61Etoposide 60130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × fosaprepitant × 1 year × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡